This study will randomize 30 healthy adult participants to one of three cohorts comprised of
six groups of 5 individuals per group to simultaneously receive PfSPZ Challenge via the ID
route. The goal will be to determine the optimal dose required to achieve 100% infectivity
(ID100) of adult volunteers with P. falciparum malaria.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)